.png){kind=logo}
™
Unlocking first-in-class biologics with genetics-inspired functional screening at scale.
Our History
Heligenics LLC., founded in 2017 by Dr. Martin Schiller of the University of Nevada, was created to fulfill the discovery of more advanced medicines.
"Heli" is derived from “hÇ£lan” an old English word that means “to heal” and “genics” which stands for genomics
Heligenics transitioned to a C corporation in late 2019. What began with just two employees and a small advisory group has grown into a dynamic team of sceients, administrative professionals, six strategic advisors, and four board members including KOLs. We have successfully executed several partnerships and are actively seeking new collaborators for our drug discovery pipeline. Our headquarters is located in a state-of-the-art research facility on the Roseman University School of Medicine Summerlin Campus.
​
Mission
Accelerate drug discovery and development by integrating high-throughput genetic engineering with high-content screening of biologics.
​
Our Approach
Developed at the University of Nevada, Las Vegas in the Schiller Laboratory of Applied Bioinformatics, the GigaAssay is Heligenics' proprietary, massively parallel biological platform. It enables the simultaneous measurement of how tens of thousands of genetic variants—or other sequence changes—impact molecular functions and cellular processes related to disease pathology and drug targets in live human cells. To date, no other high-throughput assay offers this level and accuracy of functional insight.
The GigaAssay generates functional genomics data that can be licensed for use in structure-activity relationship(SAR)-focused strategies, drug target selection, and the discovery or improvment of new biologic therapies. Heligenics is redefining how the medical industry discovers and develops new treatments.